fda warns semaglutide The U.S. Food and Drug Administration (FDA) has issued a warning to Novo Nordisk over its alleged failure to report adverse side effects, including death, in patients who took its GLP-1 medications FDA Warns About Safety of

Now, as we move forward, lets look at the possible side effects to expect and how you or your health care provider can help manage these problems

Specify the names, doses, and duration of use

Fortunately, there are ways to save money, such as using manufacturer savings cards, exploring discount programs, or discussing alternatives with your healthcare provider

02.20.25 Large analysis of diabetic patients found increase in NAION An analysis of 37.1 million adults with type 2 diabetes across 14 databases found further evidence of an association between semaglutide and NAION. 02.03.25 MDL numbers expanded ahead of February The number of pending actions in the GLP-1 MDL increased to 1,443

Insurance and pricing How much does this treatment cost